	US 12,103,956 B2
	Suicide module compositions and methods
Katharina F. S. Stengel, Oakland, CA (US)
Appl. No. 17/270,827
Filed by Caribou Biosciences, Inc., Berkeley, CA (US)
PCT Filed Sep. 30, 2019, PCT No. PCT/US2019/053903 § 371(c)(1), (2) Date Feb. 23, 2021, PCT Pub. No. WO2020/072390, PCT Pub. Date Apr. 9, 2020.
Claims priority of provisional application 62/739,483, filed on Oct. 1, 2018.
Prior Publication US 2021/0214416 A1, Jul. 15, 2021
Int. Cl. C07K 14/705 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C12N 15/86 (2006.01)

CPC C07K 14/7051 (2013.01) [A61K 35/17 (2013.01); C07K 14/70517 (2013.01); C07K 14/70539 (2013.01); C07K 14/70578 (2013.01); C12N 15/86 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C12N 2750/14143 (2013.01)]

13 Claims

1. A chimeric transmembrane protein comprising:

a suicide module comprising a ligand binding domain comprising the B cell maturation antigen extracellular domain, and a transmembrane domain, wherein the chimeric transmembrane protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51.